CCCC C4 Therapeutics, Inc.

Price Chart

Executive Summary

C4 Therapeutics presented updated Phase 1 data for cemsidomide at EHA 2026, showing a 53% overall response rate at the 100 µg RP2D in heavily pretreated RRMM patients (median 7 prior lines). Responses deepened over time, with MRD negativity achieved in two patients. The data reinforce cemsidomide's differentiated safety profile and support its development as a potential best-in-class IKZF1/3 degrader, though the stock may have limited upside given prior data disclosures and the early-stage nature of the program.

Actionable Insight

Key Facts

• 53% ORR at 100 µg RP2D in heavily pretreated RRMM patients (median 7 prior lines)
• 75% of patients received prior BCMA therapy and prior CAR-T or T-cell engager therapy
• Responses deepened over time: one patient at 100 µg deepened from PR to sCR, another from PR to VGPR
• MRD negativity achieved in two patients at 100 µg who achieved sCR and CR
• Median duration of response 7.9 months across all doses; 7 patients remain on treatment
• No discontinuations deemed related to cemsidomide; minimal dose reductions (5 patients, 7%)
• Phase 2 MOMENTUM trial (NCT07284758) is enrolling ~100 patients with ≥3 prior regimens
• Phase 1b combination trial with elranatamab (BCMAxCD3 bispecific) is ongoing

Financial Impact

No financial data provided; clinical-stage biotech with no approved products or revenue

Risk Factors

• Phase 2 MOMENTUM trial may not replicate Phase 1 ORR or durability
• Competition from other next-generation IKZF1/3 degraders and approved therapies
• Cemsidomide is investigational; regulatory approval is uncertain and years away
• Company has no approved products and relies on external financing

Market Snapshot

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status